Malek Karim, Boosalis Michael S, Waraska Kristin, Mitchell Beverly S, Wright Daniel G
Section of Hematology and Oncology, Boston University Medical Center, EBRC-405, MA 02118, USA.
Leuk Res. 2004 Nov;28(11):1125-36. doi: 10.1016/j.leukres.2004.03.003.
Six patients with bcr-abl positive AML or chronic myelogenous leukemia in blast crisis (CML-BC) were treated with the IMP-dehydrogenase (IMPDH) inhibitor, Tiazofurin, in a Phase-II trial. Tiazofurin was given by IV infusion (2200-2700 mg/m2 per day) for up to 10 days. Leukemia blasts rapidly disappeared from the circulation of patients during treatment, while mature myeloid cells in the marrow increased in number. Although these hematologic responses were transient, persisting less than 3-4 weeks, our findings confirm that Tiazofurin has anti-leukemia activity. This drug warrants further study in combination regimens with other chemotherapeutic agents for the treatment of bcr-abl positive AML and CML-BC.
在一项II期试验中，6例bcr-abl阳性急性髓系白血病（AML）或急变期慢性粒细胞白血病（CML-BC）患者接受了肌苷酸脱氢酶（IMPDH）抑制剂替唑呋林治疗。替唑呋林通过静脉输注给药（每天2200 - 2700 mg/m²），持续长达10天。治疗期间，白血病原始细胞迅速从患者循环中消失，而骨髓中的成熟髓细胞数量增加。尽管这些血液学反应是短暂的，持续时间不到3 - 4周，但我们的研究结果证实替唑呋林具有抗白血病活性。这种药物值得进一步研究与其他化疗药物联合方案用于治疗bcr-abl阳性AML和CML-BC。
